

1 The effect of influenza vaccination on trained immunity: impact on 2 COVID-19

3
4 Priya A. Debisarun¹, Patrick Struycken², Jorge Domínguez-Andrés¹, Simone J.C.F.M.
5 Moorlag¹, Esther Taks¹, Katharina L. Gösling³, Philipp N. Ostermann⁴, Lisa Müller⁴
6 Heiner Schaal⁴, Jaap ten Oever¹, Reinout van Crevel¹, Mihai G. Netea^{1,5,6*}

7 ¹Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands

8 ²Department of Occupational Health and Safety, Radboud University Medical Center, Nijmegen,
9 Netherlands

10 ³Heinrich-Heine-University Düsseldorf, Medical Faculty, Düsseldorf, Germany

11 ⁴Institute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University
12 Duesseldorf,Germany

13 ⁵Human Genomics Laboratory, Craiova University of Medicine and Pharmacy, Craiova, Romania.

14 ⁶ Germany Department for Genomics & Immunoregulation, Life and Medical Sciences Institute
15 (LIMES), University of Bonn, 53115 Bonn, Germany

16

17 *Correspondence: mihai.netea@radboudumc.nl

18

19 Mihai G. Netea, M.D., Ph.D.

20 Department of Medicine (463)

21 Radboud University Nijmegen Medical Center

22 Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands

23 Tel: +31-24-3618819

24 E-mail: mihai.netea@radboudumc.nl

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **ABSTRACT**

27

28 Every year, influenza causes 290.000 to 650.000 deaths worldwide and vaccination is encouraged to
29 prevent infection in high-risk individuals. Interestingly, cross-protective effects of vaccination against
30 heterologous infections have been reported, and long-term boosting of innate immunity (also termed
31 *trained immunity*) has been proposed as the underlying mechanism. Several epidemiological studies
32 also suggested cross-protection between influenza vaccination and COVID-19 during the current
33 pandemic. However, the mechanism behind such an effect is unknown. Using an established *in-vitro*
34 model of trained immunity, we demonstrate that the quadrivalent inactivated influenza vaccine used in
35 the Netherlands in the 2019-2020 influenza season can induce a trained immunity response, including
36 an improvement of cytokine responses after stimulation of human immune cells with SARS-CoV-2. In
37 addition, we found that SARS-CoV-2 infection was less common among Dutch hospital employees who
38 had received influenza vaccination during the 2019/2020 winter season (RR = 0,61 (95% CI,
39 0.4585 - 0.8195, $P = 0.001$). In conclusion, a quadrivalent inactivated influenza vaccine can induce
40 trained immunity responses against SARS-CoV-2, which may result in relative protection against
41 COVID-19. These data, coupled with similar recent independent reports, argue for a beneficial effect of
42 influenza vaccination against influenza as well as COVID-19, and suggests its effective deployment in
43 the 2020-2021 influenza season to protect against both infections.

44 INTRODUCTION

45 As of October 2020 there were over 37 million confirmed cases and one million deaths due to COVID-
46 19 [1]. In many cases, SARS-CoV-2 infections only cause mild symptoms that resolve spontaneously.
47 However, in the elderly or in patients with underlying health conditions such as cardiovascular disease,
48 obesity, diabetes or pre-existing lung conditions, the disease is often more severe and potentially lethal.
49 Various complications can arise and include, pulmonary edema, severe pneumonia, acute respiratory
50 distress syndrome (ARDS) and thrombotic complications among others [2]. Due to the rapid spread and
51 the high clinical and socio-economic burden of COVID-19, the efforts to prevent and combat the disease
52 have been enormous. Despite the numerous ongoing developments and clinical trials to create specific
53 vaccines against the virus, the earliest expected vaccine is likely to be deployed at least 4-6 months
54 from now and is not expected to be readily available on a large scale [3, 4].

55 In addition to COVID-19, we are still exposed to other threatening pathogens. In countries with
56 temperate climates, seasonal influenza outbreaks mainly occur in the winter, with the first cases starting
57 to appear as early as September. This leads to recurrent widespread mortality and morbidity causing 3
58 to 5 million cases of severe illness and 290.000 to 650.000 deaths per year [5]. During the previous
59 2017/2018 flu season in Europe, an estimated excess mortality of 125.000 deaths was measured [6].
60 Because of the high morbidity and socioeconomic burden of recurrent influenza epidemics, vaccination
61 has become a key strategy in protecting high-risk individuals against the flu and is therefore a widely
62 promoted public health strategy [7-10]. Despite the wide use of flu vaccines, there is contradictory
63 information on how the influenza vaccine might affect the outcome of other infections, including COVID-
64 19. The potential interaction between vaccines and infections other than their target disease, has
65 attracted a great deal of attention lately. It has been demonstrated that certain vaccines (such as bacillus
66 Calmette-Guérin (BCG), measles-containing vaccines, or oral polio vaccine) have strong beneficial
67 protective effects through long-term boosting of innate immunity, a process called *trained immunity* [11].
68 In line with this, several recent studies suggested a potential beneficial effect of influenza vaccination
69 on susceptibility to COVID-19 [12, 13]. Despite earlier reports that have shown little or opposite effects
70 of influenza vaccines on heterologous infections in children [14-19]. With the flu season on its way and
71 influenza vaccination campaigns starting off soon, it is paramount to clarify the exact effects of influenza
72 vaccination on the incidence and the disease course of COVID-19.

73 In this study, we investigated the possible induction of trained immunity responses by the influenza
74 vaccine used in the 2019-2020 winter season in the Netherlands. In addition, we assessed the
75 correlation between influenza vaccination, the incidence of COVID-19, and the disease outcome, using
76 the influenza vaccination rates in employees of the Radboud University Medical Center, one of the large
77 academic hospitals of the Netherlands.

78

79 **METHODS**

80 Blood donors

81 Buffy coats from healthy adult donors were obtained after written informed consent (Sanquin blood bank,
82 Nijmegen, The Netherlands). The study was approved by the Arnhem- Nijmegen Medical Ethical
83 Committee.

84

85 *In-vitro* influenza training model

86 Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (VWR, Tingalpa,
87 Australia) density gradient isolation and resuspended in RPMI 1640+ (Dutch modified, ThermoFisher,
88 Waltham, MA, USA) culture medium supplemented with 50 mg/mL gentamicin, 2 mM glutamax
89 (ThermoFisher), and 1 mM pyruvate (ThermoFisher). PBMCs were diluted to a concentration of 5×10^6
90 cells/ml and 100 μ l (500.000 cells) of cell suspension was added to each well of a 96-wells round bottom
91 plate. PBMCs were stimulated with Vaxigrip Tetra® (Sanofi Pasteur Europe), which is similar to the
92 vaccine used in the 2019/2020 vaccination campaign in the Netherlands. The influenza vaccine contains
93 15 grams of Hemagglutinin each from 4 inactivated, non-adjuvanted virus strains (1 A/Guangdong-
94 Maonan/SWL1536/2019 (H1N1)pdm09-like strain, (A/GuangdongMaonan/SWL1536/2019, CNIC-1909,
95 2 A/Hong Kong/2671/2019 (H3N2) –like strain, (A/Hong Kong/2671/2019, IVR-208), 3
96 B/Washington/02/2019 – like strain (B/Washington/02/2019, wild type), 4 B/Phuket/3073/2013-like strain
97 (B/Phuket/3073/2013, wild type). Vaxigrip Tetra® was added to the wells in 10, 50, 100 and 400-fold
98 dilutions in 1640 culture medium (RPMI medium; Invitrogen, CA, USA) supplemented with 10% human
99 pooled serum. In addition, 5 μ g/ml of BCG (Bacille Calmette- Guérin, SSI, Denmark) was added to half
100 of the wells to investigate the potency of influenza vaccine to enhance trained immunity induced by

101 BCG. PBMCs were incubated for 24h after which the supernatants were harvested. Cells were washed
102 with warm PBS and medium was refreshed. PBMCs were then left to rest in culture medium for another
103 5 days, after which (on day 6) they were restimulated with LPS (10 ng/mL) or inactivated SARS-CoV-2
104 [20] (SARS-CoV-2 NRW-42 isolate, 40x diluted, TCID50/mL 6.67×10^4) for 24 hours. On day 7,
105 supernatants were harvested and stored at -20°C for cytokine measurements (Figure 1).

106

107 Lactate-dehydrogenase (LDH) assay

108 Cytotoxicity was measured using LDH concentrations in fresh supernatants collected after 24 h
109 stimulation, using the Cyto-Tox96 Non-Radioactive cytotoxicity assay (Promega, WI, USA).

110

111 Cytokine measurements

112 Cytokine concentrations were determined in 24 h supernatants (TNF- α , IL-6, IL-1 β) and 7 day
113 supernatants (TNF- α , IL-6, IL-1RA, and IFN- γ) using commercial ELISA kits (R&D systems, Bio-
114 Techne, Minneapolis, Minnesota, USA) according to the manufacturer's protocol.

115

116 Observational data healthcare workers

117 The Radboudumc hospital registration database of SARS-CoV-2 PCR-positive healthcare workers as
118 of June 1st 2020 was consulted. The corresponding influenza vaccination status of healthcare workers
119 was retrieved from the database of the Department of Occupational Health and Safety of the hospital,
120 as well as the total influenza vaccination coverage rate (VCR) of the Radboudumc during the flu season
121 of 2019/2020. Additionally, SARS-CoV-2 positive employees were sent a questionnaire to assess
122 disease duration, severity and comorbidities. Disease duration was measured as the number of days
123 between the SARS-CoV-2 PCR test and the first day employees resumed their work. All hospital
124 employees are equally offered an influenza vaccination every year. However, SARS-CoV-2 testing in
125 the beginning of the pandemic was only available for employees who were indispensable for patientcare,
126 due to shortage of testing materials. Giving the observational nature of this study and the use of short
127 questionnaires only, no ethical approval was required.

128

129 Data analysis

130 Hospital database analysis was done using IBM SPSS statistics 25. To assess the association between
131 COVID-19 incidence and influenza vaccination status, a Chi-square test was used. No correction for
132 confounding was possible because no individual characteristics were available in the SARS-CoV-2 PCR
133 negative health care workers; only influenza vaccination status data for the entire group was known.
134 Missing values of other variables were left out of analysis. Cytokine and LDH concentrations were
135 analyzed using Wilcoxon matched-pairs signed rank test. Absolute cytokine concentrations were
136 determined after 24 hours in influenza vaccine stimulated conditions (with and without BCG) and
137 compared with unstimulated conditions. As a readout for trained immunity responses, influenza vaccine-
138 primed (at day 6 LPS and SARS-CoV-2 restimulated) conditions were compared to RPMI conditions as
139 a negative control and BCG only conditions as a positive control. To assess synergistic effects on trained
140 immunity, combined influenza vaccine and BCG stimulated conditions were also compared. LDH values
141 were calculated to percentages of cell death, with lysed cells as a positive control. Data were analyzed
142 using Graphpad 8.02 (La Jolla, San Diego, CA, USA). A two-sided P-value below .05 (*) or below .01
143 (***) was considered statistically significant. Data are shown as means \pm SEM.

144

145 **RESULTS**

146 **A quadrivalent inactivated influenza vaccine (Vaxigrip Tetra®) amplifies cytokine production in**
147 **human PBMCs**

148 Freshly isolated PBMCs from healthy donors (n=9) were stimulated for 24 h with Vaxigrip Tetra® in 10,
149 50, 100, or 400 times dilutions alone or in presence of BCG. Stimulation with Vaxigrip Tetra® alone did
150 not result in increased production of IL-6, TNF- α , or IL-1 β by itself. However, the combination of the
151 influenza vaccine with BCG induced significantly higher cytokine production compared to BCG alone,
152 suggesting a synergistic effect between these two vaccines. This effect was dose-dependent, with
153 higher dilutions of the influenza vaccine associated with a higher cytokine production (Figure 2). To rule
154 out cell death as a cause of cytokine release, LDH concentrations were measured in fresh supernatants

155 collected after 24 h stimulation and showed no differences between conditions (Supplementary Figure
156 1), arguing against toxic effects of the vaccines.

157

158 **Vaxigrip Tetra® induces trained immunity and amplifies BCG-induced trained immunity**

159 In a separate set of experiments, 6 days after an initial 24h period of training of human PBMCs with the
160 quadrivalent inactivated influenza vaccine, the cells were restimulated with heat-inactivated SARS-CoV-
161 2 or lipopolysaccharide (LPS) from *Escherichia coli* for another 24h. Training with different
162 concentrations of the influenza vaccine induced the production of higher levels of IL-1RA after
163 restimulation with SARS-CoV-2 for all the dilutions tested, as well as for LPS (400x dilution) (figure 3A,
164 B). Combining the influenza vaccine with BCG abrogated this effect. Trained immunity responses on
165 the production of IL-6 were observed in almost all influenza vaccine-primed conditions after restimulation
166 with LPS (all dilutions) and heat-inactivated SARS-CoV-2 (10x, 100x, 400x dilutions) (Figure 3C). In
167 addition, induction of trained immunity by BCG was amplified by training with the combination of BCG
168 and Vaxigrip Tetra® (Figure 3D). PBMC training with the influenza vaccine alone also enhanced IFN- γ
169 production stimulated with SARS-CoV-2, but not LPS (Figure 3E). The combination of BCG with Vaxigrip
170 Tetra® also induced higher responses upon restimulation with SARS-CoV-2, but not with LPS (Figure
171 3F). None of the influenza vaccine-primed conditions produced any significant release of TNF- α after
172 SARS-CoV-2 restimulation. Only in BCG-primed conditions after LPS restimulation a higher induction
173 of TNF- α was present (Figure 3G, H). Overall, training with various concentrations of the influenza
174 vaccine enhanced cytokine production upon restimulation, and also amplified the trained immunity
175 inducing capacity of BCG.

176

177 **Quadrivalent inactivated influenza vaccination is associated with lower COVID-19 incidence**

178 As of June 1st 2020, at the end of the first wave of the COVID-19 pandemic in the Netherlands, Radboud
179 University Medical Center counted a total of 10.631 employees of which 184 were documented as
180 SARS-CoV-2 PCR-positive according to the hospital's database. The average age of the employees
181 was 41 years and 42 years in the SARS-CoV-2 positive and negative group, respectively. Female

182 employees made up a slightly higher proportion of the SARS-CoV-2 positive group (79%) compared to
183 the SARS-CoV-2 negative group (70%) (Table 1).

184 To investigate the effect of influenza vaccination on the incidence of COVID-19, we gathered the
185 influenza vaccination status of SARS-CoV-2 PCR positive employees in the Radboud University Medical
186 Center and compared it to the influenza vaccination coverage rates in hospital employees unaffected
187 by COVID-19. Within the SARS-CoV-2 positive group, 42% (77/184) of the individuals were vaccinated
188 with influenza during the flu season of 2019/2020, whereas the total influenza vaccine coverage rate for
189 that season in SARS-CoV-2 negative personnel was 54% (5664/10447). This resulted in a 2.23%
190 incidence of COVID-19 in the non-vaccinated individuals, while the incidence of COVID-19 in influenza
191 vaccinated individuals was 1.33%: thus, a statistically significant negative association between influenza
192 vaccination and COVID-19 incidence of $RR = 0,61$ (95% CI, 0.46 - 0.82, $P = 0.001$) ($X^2(1, N = 10632) =$
193 $11,41$, $p = .0008$) (Figure 4A, B) was identified. We found no association between influenza vaccination
194 status and COVID-19 duration: the mean disease duration in influenza-unvaccinated personnel was
195 17 ± 9 days, and 18 ± 11 days in vaccinated individuals ($P = .23$). It is important to note that 76% of SARS-
196 CoV-2 positive employees had direct patient contact, as opposed to 42% in SARS-CoV-2 negative
197 personnel.

198 Among SARS-CoV-2 positive employees, only one of the individuals was hospitalized, but did not need
199 any intensive-care treatment. No SARS-CoV-2 related deaths among positive employees occurred. The
200 mean ages were 39 and 44 years for influenza unvaccinated and vaccinated employees within the
201 SARS-CoV-2 positive group respectively. There were no significant differences between sex, patient
202 contact or comorbidities in both groups (Table 2).

203

204 **DISCUSSION**

205 In the present study, we demonstrate that the tetravalent inactivated influenza vaccine Vaxigrip Tetra®
206 induces trained immunity in an established *in-vitro* model, resulting in improved responsiveness of
207 immune cells to SARS-CoV-2 stimulation. In addition, Vaxigrip Tetra® amplifies the capacity of the BCG
208 vaccine to induce trained immunity [21]. These results are in line with a previous study from our group
209 in which 40 healthy volunteers received a trivalent influenza vaccine 14 days after receiving either BCG
210 or placebo [22]. Whilst BCG exhibited a broad increase of pro-inflammatory cytokines for a larger set of

211 unrelated pathogens, the influenza vaccine showed more selective augmentation of cytokine responses
212 after *ex-vivo* restimulation of peripheral blood leukocytes, similar to our observations. In addition, we
213 complement these data with an epidemiological analysis that shows an inverse association between
214 influenza vaccination using a quadrivalent inactivated influenza vaccine, and COVID-19 incidence. This
215 suggests a protective effect of the flu vaccine against infection with SARS-CoV-2.

216

217 Our data are in line with several recent ecological studies (Table 3). Hernandez et al. employed publicly
218 available data from the 2019/2020 influenza vaccination season in Italy with a quadrivalent vaccine, a
219 trivalent inactivated vaccine, and an inactivated, adjuvanted trivalent vaccine to calculate a linear
220 regression model to predict the COVID-19 mortality in vaccinated adults over 65 years of age. They
221 found a moderate to strong negative correlation ($r = -.5874$, $n = 21$, $P = .0051$) between influenza
222 vaccination and mortality in the elderly, suggesting that if the influenza VCR was higher, less individuals
223 died from COVID-19 [23]. Another Italian study used data from 21 Italian regions and also found a
224 negative correlation between influenza VCR and SARS-CoV-2 seroprevalence, hospitalization rates,
225 ICU admissions as well as COVID-19 related mortality in the elderly. Multivariable analysis revealed a
226 R^2 of 0.88, 0.82, 0.70 and 0.78 for all the outcomes respectively. In other words, influenza vaccination
227 strongly predicts the variance in the aforementioned outcomes [13]. Zanettini et al. concluded that a
228 10% increase in VCR could decrease SARS-CoV-2 related mortality by 28 percent, adjusted for several
229 variables [24]. Arokiaraj also described the existence of negative correlations between VCR and COVID-
230 19 related morbidity and mortality in individuals over 65 years of age in members of the Organisation for
231 Economic Cooperation and Development (OECD) countries. However, these correlations were not
232 substantiated by statistical evidence, making it difficult to draw firm conclusions [25]. On the contrary,
233 Lisewski et al. found an increased COVID-19 risk in 28 OECD countries as a result of influenza
234 vaccination, assessed with a Pearson correlation coefficient of $r = 0.58$ (95CI: 0.27 to 0.78; $p=0.001$),
235 between VCR and attack rates [26]. A recent report from the Evidence-based medicine, public health
236 and environmental toxicology consortium (EBMPHET), compared the vaccination coverage rate among
237 elderly (≥ 65 years of age) and COVID-19 infection risk and disease severity in Europe and the USA.
238 They found a statistically significant positive correlation between the VCR and reported COVID-19
239 incidence in Europe ($r = 0.66 \pm 0.13$, $P = .000017$) as well as mortality for Europe ($r = 0.68 \pm 0.13$, $p =$
240 0.000006) and the USA, but confounding factors were not taken into account [27].

241

242 Overall, the majority of the ecological data are leaning to a possible protective effect of the influenza
243 vaccines. However, ecological studies also have several limitations. In this respect, there can be
244 systematic differences in how countries and areas report disease, mortality and exposures. For
245 example, in Italy any deceased person with a positive SARS-CoV-2 test is registered as a SARS-CoV-
246 2 related death [28]. Besides this, information on confounding factors and effect modifiers can be
247 missing and correction for confounders sometimes is impossible, causing over- or underestimation of
248 outcomes. Wals et al. reviewed 18 studies in which influenza and its associations with other respiratory
249 infections as well as COVID-19 were assessed. The conclusion was that live influenza vaccines are
250 safe, however data on trivalent inactivated vaccines were not reassuring, followed by the suggestion to
251 vaccinate with live vaccines when possible [29]. Aside from ecological studies, there is a recent cross
252 sectional study conducted in Brazil, also supportive of a negative correlation between an inactivated
253 trivalent influenza and COVID-19 attributed mortality (17% lower odds, 95%CI [0.75,0.89]), need of
254 intensive care treatment (8% lower odds, 95%CI [0.86,0.99]) and need of invasive respiratory support
255 (18% lower odds, 95%CI [0.74,0.88]). Correction for comorbidities, several sociodemographic factors
256 and healthcare facilities was performed [30].

257

258 Many of these studies hypothesized that trained immunity may be the mechanism underlying these
259 observations [21, 31-33]. The most extensively studied vaccine that induces trained immunity is BCG,
260 which is currently being examined for its putative protective effects against COVID-19 duration and
261 severity in several clinical trials (NCT04328441, NCT04348370, NCT04327206, NL8609). Although this
262 property is usually assigned to live vaccines [34], whether influenza vaccination can also induce trained
263 immunity was not known. In this study we also found that Vaxigrip Tetra® induces a trained immunity
264 response towards both SARS-CoV-2 and the TLR4 ligand LPS, and in addition synergized with the
265 trained immunity effects of BCG. The fast induction of cytokine responses at the beginning of the
266 infection is crucial to decrease the viral load and prevent systemic inflammation. The amplified IL-6
267 response activates acute phase proteins, stimulates effector T-cell development along with antibody
268 secretion, forming the linkage between innate and adaptive immunity, thus contributing to the clearance
269 of the infection [35]. On the other hand, anti-inflammatory cytokines such as IL-1Ra are necessary to

270 fine-tune the inflammation and counteract excessive inflammation. In our experimental setup we
271 observed both, increased production of IL-6 paralleled with IL-1Ra, after stimulation with the influenza
272 vaccine and BCG. This confirms that these cytokines might contribute to keeping a balance in the
273 inflammatory status of the individual [36]. In addition, trained immunity is also known to be induced in
274 NK cells, which play an important role in containing viral infections, among others through their
275 production of IFN- γ . The increased IFN- γ produced after stimulation with the influenza vaccine and BCG,
276 as shown here, can indicate the long-term functional reprogramming of NK cells, which then activate
277 macrophages to further orchestrate the clearing of pathogens [37].

278

279 Our study also has important limitations. The database analysis performed in this study did not allow to
280 correct for confounders, as we were not able to access data of individual influenza vaccination status in
281 SARS-CoV-2 negative employees. An important confounder is the difference in the rate of the direct
282 contact with patients between employees who developed SARS-CoV-2 or not, since this was the
283 variable unevenly distributed among the two groups, with less direct patient contact in SARS-CoV-2
284 negative employees. However, earlier studies have reported that most of the SARS-CoV-2 infections in
285 hospital personnel occur in society, rather than through patient contact in the hospitals [38-40].
286 Furthermore, we had no information on comorbidities in SARS-CoV-2 negative personnel or other
287 exposures outside the hospital environment. Within the SARS-CoV-2 positive group, part of the
288 individuals did not return the questionnaire which included information about comorbidities. These
289 missing values were left out and could not be computed which can affect the analysis as well. Lastly,
290 one cannot rule out healthy-vaccinee bias, and caution is always required when translating survey data
291 into real-life conditions.

292

293 In conclusion, we provide observational data suggesting a potentially protective role of the quadrivalent
294 inactivated influenza vaccine on COVID-19 incidence. In addition, we report first insights in the
295 immunological mechanisms underlying these observations. We show that a quadrivalent inactivated
296 influenza vaccine can induce trained immunity, and the plausible mechanisms through which an
297 enhanced antiviral state is acquired after vaccination. Considering these data, and with at least several
298 months more needed until a specific SARS-CoV-2 vaccine is available, influenza vaccination may

299 contribute not only to reduction of influenza but also to the COVID-19-related burden on the healthcare
300 system. While our data show that earlier influenza vaccination is safe in relation to a later SARS-CoV-2
301 infection, we recommend vaccination in the absence of active COVID-19, because of the theoretical
302 possibility to induce a cytokine storm by an enhanced immune response if the vaccine is given during
303 an active infection. Additionally, our data suggest that the presence of a previous BCG vaccination prior
304 to the influenza vaccination could lead to enhanced responses and improved protection, raising the
305 possibility to conduct clinical trials to assess this hypothesis.

306

307 **ACKNOWLEDGEMENTS**

308 MGN was supported by a Spinoza Grant of the Netherlands Association for Scientific Research and an
309 ERC Advanced Grant (no. 833247). PNO, LM and HS were supported by the Jürgen Manchot
310 Foundation. We thank the Department of Occupational Health and Safety (Radboud University Medical
311 Center, Nijmegen) for providing Vaxigrip Tetra®. We also thank Yuri Elsas (Radboud University,
312 Nijmegen) for assistance in collecting the questionnaires.

313

314 **AUTHOR CONTRIBUTIONS**

315 PAD and MGN designed the studies. PAD conducted the experiments, analysis and conceptualized the
316 manuscript. All coauthors provided input on draft versions and approved the final version.

317

318 **COMPETING INTERESTS**

319 The authors declare no competing interests.

320

321

TABLES AND FIGURES

Table 1 - Baseline characteristics of SARS-CoV-2 negative and positive employees

Characteristic*	SARS-CoV-2 negative (n=10447)	SARS-CoV-2 positive (n=184)
Gender, female†	7338 (70,2)	146 (79,3)
Gender, male †	2986 (28,6)	39 (21,2)
Age, years †	42 ± 12,9	41 ± 12,3
Direct patient-contact	4412 (42,2)	139 (75,5)

* Mean ± SD for continuous variables, and N (%) for categorical variables

† Age and gender were not provided for 123 employees in the SARS-CoV-2 negative group

Table 2 - Baseline characteristics of influenza vaccinated and unvaccinated employees

Characteristic*	SARS-CoV-2 positive	
	Influenza unvaccinated (n=107)	Influenza vaccinated (n=77)
Gender, female	85 (79,4)	61 (79,2)
Gender, male	22 (20,6)	16 (20,1)
Age, years	39 ± 12,2	44 ± 12,0
Direct patient-contact	77 (73,0)	62 (80,6)
Total comorbidities †	9 (20)	10 (19)

* Mean ± SD for continuous variables, and N (%) for categorical variables

† comorbidities were not known for 58 influenza unvaccinated and 25 influenza vaccinated individuals

Table 3 – Studies on the association between influenza vaccination and COVID-19 related outcomes

Author, year	Design	Methods	Main results
Hernandez et al., 2020	Ecological study	COVID-19 mortality in elderly (> 65 years) and influenza VCR were analyzed across 21 regions in Italy. No correction for confounding was performed. Data up to May 2020 were used.	Moderate to strong, negative correlation between influenza vaccination and COVID-19 attributable mortality. ($r = -.5874$, $n = 21$, $P = .0051$)
Amato et al., 2020	Ecological study	Influenza VCR and SARS-CoV-2 seroprevalence, hospitalization rates, ICU admissions as well as COVID-19 related mortality in the elderly (>65 years) in Italy were assessed. Correction for confounders was performed for several comorbidities, economic and environmental variables. COVID-19 related data were collected from March 2020 until June 2020. Influenza VCR was calculated based on extrapolation of the last five years' vaccination rates.	Negative correlation between influenza vaccination and SARS-CoV-2 seroprevalence, hospitalization rates, ICU admission as well as COVID-19 attributable mortality. (R^2 of 0.88, 0.82, 0.70 and 0.78 respectively)
Zanettini et al., 2020	Ecological study	COVID-19 mortality in elderly (> 65 years) and influenza VCR were analyzed across all states of the USA. Correction for confounding was performed for several socio-economic-, demographic-, healthcare-, race- and comorbidity- related variables. Data from January 2020 until June 2020 were used.	Negative association between influenza vaccination and COVID-19 attributable mortality, where every 10% increase in influenza VCR, causes a 28% decrease in COVID-19 related death. (MRR = 0.72; 95%CI: 0.58-0.89)
Arokiaraj, 2020	Ecological study	COVID-19 morbidity and mortality in elderly (> 65 years) and influenza VCR were analyzed across OECD countries.	Negative correlations between influenza vaccination and the COVID-19 epidemiological parameters. However, lacking of statistical analysis.
Lisewski et al., 2020	Ecological study	COVID-19 incidence in elderly (> 65 years) and influenza VCR were analyzed across 29 OECD countries.	Positive correlation between influenza vaccination and COVID-19 attack rates. ($r = 0.58$; 95%CI: 0.27 to 0.78; $P = .001$)
EBMPHET consortium, 2020	Ecological study	COVID-19 mortality in elderly (> 65 years) and influenza VCR were analyzed across Europe and the USA. Data up to May 2020 were used. No correction for confounding was performed.	Positive correlation between influenza vaccination and COVID-19 incidence in Europe ($r = 0.66 \pm 0.13$, $P = .000017$) and the USA ($r = 0.50 \pm 0.14$, $P < .05$). Positive correlation between influenza vaccination and COVID-19 attributable mortality in Europe ($r = 0.68 \pm 0.13$, $p = 0.000006$) and the USA ($r = 0.50 \pm 0.14$, $P < .05$).
Fink et al., 2020	Cross-sectional study	Associations between COVID-19 related mortality, intensive care treatment, need of invasive respiratory support and influenza VCR were analyzed in 92.664 clinically and molecularly confirmed COVID-19 cases in Brazil. Correction for confounding was performed for several comorbidities, sociodemographic factors and healthcare facilities.	Positive correlation between influenza vaccination and COVID-19 attributed mortality (17% lower odds, 95%CI [0.75,0.89]). Positive correlation between influenza vaccination and need of intensive care treatment (8% lower odds, 95%CI [0.86,0.99]). Positive correlation between influenza vaccination and need of invasive respiratory support (18% lower odds, 95%CI [0.74,0.88])

ICU, intensive care unit; OECD, Organization for Economic Cooperation and Development; VCR, vaccination coverage rate.




Figure 1 - *In-vitro* trained immunity experiments with quadrivalent inactivated influenza vaccine and BCG

PBMCs from healthy donors were isolated and seeded in a 96-wells round bottom plate. Then 4 dilutions (10x, 50x, 100x, 400x) of the quadrivalent inactivated influenza vaccine (Vaxigrip Tetra®) were added to the cells. In other wells, the vaccine was combined with BCG (5µg/mL) and control wells only contained RPMI. After 24 h the supernatant was collected and cells were washed. Fresh RPMI was added to the cells and left to incubate for another 5 days. On day 6, the PBMCs were restimulated with LPS (10 ng/mL) or inactivated SARS-CoV-2 (40x diluted, TCID₅₀/mL 6.67*10⁴) for another 24 h. On day 7, the supernatants were collected and stored for cytokine measurements.




Figure 2 - Addition of quadrivalent inactivated influenza vaccine increases 24 h cytokine production in PBMCs stimulated with BCG

Stimulation of PBMCs with several dilutions of the quadrivalent influenza vaccine (10x, 50x, 100x, 400x) did not result in increased concentrations of IL-6, IL-1 β , and TNF- α after 24 h compared to RPMI conditions. Vaxigrip Tetra® increased cytokine production induced by BCG (5 μ g/ml). (Wilcoxon matched pairs signed rank test, $n = 9$, * = $P < .05$, ** = $P < .01$).




Figure 3 - Inactivated quadrivalent influenza vaccine induces trained immunity after restimulation with SARS-CoV-2 and LPS and influences BCG-induced training. PBMCs were trained with several dilutions of the inactivated quadrivalent vaccine (10x, 50x, 100x, 400x) with or without BCG (5 µg/mL), restimulated at day 6 with LPS (10 ng/ml) or SARS-CoV-2 ((40x diluted, TCID50/mL 6.67*10e4) for 24 h and compared to RPMI conditions. Vaxigrip Tetra® amplified IL-1Ra (A, B) and IL-6 (C, D) responses after SARS-CoV-2 or LPS restimulation, compared to stimulation of naïve PBMCs. Training with BCG diminished the training effect of Vaxigrip Tetra® on IL-1Ra production, but increased IL-6 responses even more. A significant increase in IFN-γ production was seen after training of PBMCs with 10x dilutions of the influenza vaccine and restimulation with SARS-CoV-2. The combination of the influenza vaccine with BCG induced even more IFN-γ than BCG alone (E, F). No significant increase in TNF-α by Vaxigrip Tetra® was observed after restimulation with SARS-CoV-2 (G). Vaxigrip Tetra® enhanced TNF production upon LPS restimulation, but only in combination with BCG (H). (Wilcoxon matched pairs signed rank test, $n=7-9$, * = $P < .05$, ** = $P < .01$)




Figure 4 - Influenza vaccination is associated with lower COVID-19 incidence

In SARS-CoV-2 positive employees, 42% (77/184) was influenza vaccinated. (A) In SARS-CoV-2 negative personnel 54% (5664/10447) was vaccinated, (B) Vaccination was associated with lower COVID-19 incidence RR = 0,61 (95% CI, 0.4585 - 0.8195, $P = 0.001$), ($X^2(1, N = 10632) = 11,41, P = .0008$). No association was found between vaccination status and COVID-19 duration ($X^2(42, N = 172) = 48,41 p = .23$). (C) The mean disease duration in influenza unvaccinated personnel was 17 ± 9 days and 18 ± 11 days in vaccinated individuals.

REFERENCES

1. WHO. *World health organisation, COVID-19 dashboard*. 2020 [cited 2020 01-10-2020]; Available from: <https://covid19.who.int/>.
2. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study*. *Lancet*, 2020. **395**(10223): p. 507-513.
3. Chen, W.H., et al., *The SARS-CoV-2 Vaccine Pipeline: an Overview*. *Curr Trop Med Rep*, 2020: p. 1-4.
4. Thanh Le, T., et al., *The COVID-19 vaccine development landscape*. *Nat Rev Drug Discov*, 2020. **19**(5): p. 305-306.
5. Organisation, W.H., [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)). 2020.
6. Nielsen, J., et al., *European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?* *Clin Microbiol Infect*, 2019. **25**(10): p. 1266-1276.
7. Peteranderl, C., S. Herold, and C. Schmoldt, *Human Influenza Virus Infections*. *Semin Respir Crit Care Med*, 2016. **37**(4): p. 487-500.
8. WHO. *World Health Organization Fact Sheet on Influenza; 2014*. 2014 [cited 2020 10 May]; Available from: <http://www.who.int/mediacentre/factsheets/fs211/en/>.
9. Reed, C., et al., *Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season*. *MMWR Morb Mortal Wkly Rep*, 2014. **63**(49): p. 1151-4.
10. Grohskopf, L.A., et al., *Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season*. *MMWR Morb Mortal Wkly Rep*, 2015. **64**(30): p. 818-25.
11. Netea, M.G., et al., *Defining trained immunity and its role in health and disease*. *Nat Rev Immunol*, 2020. **20**(6): p. 375-388.
12. Pawlowski, C. and A. Puranik, *Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations*. 2020. **2020**.
13. Amato, M., et al., *Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study*. *Vaccines (Basel)*, 2020. **8**(3).
14. Kelly, H., et al., *Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case-Control Study*. *Pediatr Infect Dis J*, 2011. **30**(2): p. 107-11.
15. Rikin, S., et al., *Assessment of temporally-related acute respiratory illness following influenza vaccination*. *Vaccine*, 2018. **36**(15): p. 1958-1964.
16. Cowling, B.J., et al., *Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine*. *Clin Infect Dis*, 2012. **54**(12): p. 1778-83.
17. Mawson, A.R., et al., *Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12-year old U.S. children*. *Journal of Translational Science*, 2017. **3**.
18. Dierig, A., et al., *Epidemiology of respiratory viral infections in children enrolled in a study of influenza vaccine effectiveness*. *Influenza Other Respir Viruses*, 2014. **8**(3): p. 293-301.
19. Sundaram, M.E., et al., *Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness*. *Clin Infect Dis*, 2013. **57**(6): p. 789-93.
20. Ramani, A., et al., *SARS-CoV-2 targets neurons of 3D human brain organoids*. *EMBO J*, 2020: p. e106230.
21. Kleinnijenhuis, J., et al., *Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes*. *Proc Natl Acad Sci U S A*, 2012. **109**(43): p. 17537-42.
22. Leentjens, J., et al., *BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study*. *J Infect Dis*, 2015. **212**(12): p. 1930-8.
23. Marin-Hernandez, D., R.E. Schwartz, and D.F. Nixon, *Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy*. *J Med Virol*, 2020.
24. Zanettini, C., et al., *Influenza Vaccination and COVID19 Mortality in the USA*. *medRxiv*, 2020.
25. MC., A., *Correlation of influenza vaccination and the COVID-19 severity*. *SSRN*, 2020.
26. Lisewski and A. Martin, *Association between Influenza Vaccination Rates and SARS-CoV-2 Outbreak Infection Rates in OECD Countries*. *SSRN*, 2020.
27. consortium, E., *COVID-19 Severity in Europe and the USA: Could the seasonal influenza vaccination play a role?* *SSRN*, 2020.
28. Onder, G., G. Rezza, and S. Brusaferro, *Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy*. *JAMA*, 2020. **323**(18): p. 1775-1776.
29. P. De Wals and M. Divangahi, *Could seasonal influenza vaccination influence COVID-19 risk?* *medRxiv*, 2020.
30. Fink, G. and N. Orlova-Fink, *Inactivated Trivalent influenza vaccien is associated with lower mortality among Covid-19 patients in Brazil*. *medRxiv*, 2020.
31. Netea, M.G., et al., *Trained immunity: A program of innate immune memory in health and disease*. *Science*, 2016. **352**(6284): p. aaf1098.
32. Arts, R.J., et al., *Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity*. *Cell Metab*, 2016. **24**(6): p. 807-819.

33. Arts, R.J.W., et al., *Immunometabolic Pathways in BCG-Induced Trained Immunity*. Cell Rep, 2016. **17**(10): p. 2562-2571.
34. Blok, B.A., et al., *Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines*. J Leukoc Biol, 2015. **98**(3): p. 347-56.
35. Tanaka, T., M. Narazaki, and T. Kishimoto, *IL-6 in inflammation, immunity, and disease*. Cold Spring Harb Perspect Biol, 2014. **6**(10): p. a016295.
36. Moorlag, S., et al., *The role of the interleukin-1 family in trained immunity*. Immunol Rev, 2018. **281**(1): p. 28-39.
37. Kleinnijenhuis, J., et al., *BCG-induced trained immunity in NK cells: Role for non-specific protection to infection*. Clin Immunol, 2014. **155**(2): p. 213-9.
38. Rhee, C., et al., *Incidence of Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center*. JAMA Netw Open, 2020. **3**(9): p. e2020498.
39. Rickman, H.M., et al., *Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital*. Clin Infect Dis, 2020.
40. Wake, R.M., et al., *Reducing nosocomial transmission of COVID-19: implementation of a COVID-19 triage system*. Clin Med (Lond), 2020. **20**(5): p. e141-e145.